NMN and NR Pharmacokinetics: How These NAD Precursors Actually Work in Women

What NMN and NR Are, and Why the Distinction Matters

NMN and NR are two different molecules that both serve as precursors to NAD+ (nicotinamide adenine dinucleotide), the coenzyme your cells use for energy metabolism, DNA repair, and sirtuin signaling. They are not the same drug with different spellings. Their chemical structures differ, their absorption routes differ, and the enzymes required to convert them to NAD+ differ. Understanding which molecule does what, and how each behaves inside a woman's body, is the only way to make sense of the clinical trial results.

Chemical Identity

NMN (nicotinamide mononucleotide) is a nucleotide. Its molecular formula is C11H15N2O8P, and it sits one enzymatic step closer to NAD+ than NR does. NR (nicotinamide riboside) is a nucleoside, lacking the phosphate group. Both are naturally present in trace amounts in foods such as edamame, broccoli, and cow's milk, but dietary amounts are far below the doses used in supplementation trials.

Why NAD+ Declines and Why Women Should Care

NAD+ concentrations fall roughly 50% between young adulthood and midlife in human tissues, a decline that has been linked to mitochondrial dysfunction, impaired DNA repair, and metabolic inefficiency. This matters specifically for women because estrogen appears to support NAD+ biosynthesis through the de novo (tryptophan-kynurenine) pathway. As estrogen falls during perimenopause and menopause, this biosynthetic support is withdrawn, potentially accelerating the age-related NAD+ decline on a female-specific timeline. Direct measurement of NAD+ by life stage in women remains an active research gap, but the mechanistic basis for this concern is real.

Absorption: How NMN and NR Get Into Your Bloodstream

NMN Absorption: A Transporter-Dependent Process

For years, researchers assumed NMN could not cross the intestinal membrane intact because of its phosphate group and because phosphorylated nucleotides generally require dephosphorylation before cellular uptake. That assumption was revised when Grozio et al. Identified Slc12a8, a specific NMN transporter expressed in the small intestinal brush-border epithelium of mice. The transporter allows NMN to enter intestinal cells without being first converted to NR.

Whether the human ortholog of Slc12a8 performs the same function is not yet confirmed in controlled human intestinal tissue studies. This is a meaningful evidence gap. Most human pharmacokinetic data instead measure blood metabolite levels after oral dosing rather than directly imaging intestinal transport.

In the first dedicated human NMN pharmacokinetic study, Irie et al. (2020) gave 12 healthy men a single oral dose of 100, 250, or 500 mg NMN and measured plasma concentrations over 6 hours. NMN reached peak plasma concentration within approximately 2-3 minutes at the lowest dose and about 15 minutes at the 500 mg dose. NAD+ in whole blood rose measurably within 1-2 hours. This trial enrolled only men. No equivalent single-dose PK study in women has been published as of the date of this article.

NR Absorption: Rapid, Partially Pre-Converted

NR is absorbed more readily than NMN because it lacks the phosphate group and does not require a dedicated transporter in the same way. After oral ingestion, NR is partly converted to nicotinamide (NAM) in the gut lumen and portal circulation before it ever reaches systemic blood. Trammell et al. (2016) characterized this in humans, showing that orally dosed NR raises blood NAD+ and NAD+ metabolites within 2-4 hours, with significant interindividual variability. A portion of the dose is effectively "lost" as NAM before reaching target tissues.

This pre-conversion matters clinically. If your goal is tissue-level NAD+ repletion rather than simply raising serum NAM, the fraction of the oral NR dose that survives as intact NR to peripheral tissues is smaller than the total dose suggests.

Sublingual and Alternative Delivery Routes

Some manufacturers market sublingual NMN, claiming it bypasses first-pass intestinal and hepatic metabolism to deliver NMN directly into systemic circulation via the sublingual venous plexus. The pharmacokinetic rationale is sound in principle. No published human PK trial has directly compared sublingual versus oral NMN absorption using equivalent doses, controlled conditions, and appropriate statistical power in either sex. Claims of superior bioavailability from sublingual formulations are, at this time, manufacturer-generated rather than independently verified.

Distribution: Where NMN and NR Go After Absorption

Tissue-Level NAD+ and the Question of Selectivity

Once absorbed and converted to NAD+, the coenzyme is not distributed freely across all tissues equally. NAD+ itself does not readily cross cell membranes. Tissues synthesize NAD+ locally from circulating precursors, which means the distribution of the precursor (NMN or NR) to a given tissue determines whether that tissue benefits.

Yoshino et al. (2021, Science) conducted the first rigorous human trial examining NMN's effect in a female population, enrolling 25 postmenopausal women with prediabetes or overweight who were randomized to NMN 250 mg/day orally or placebo for 10 weeks. Muscle biopsy NAD+ metabolomics confirmed that NMN supplementation increased skeletal muscle NAD+ and NAD+ metabolite concentrations relative to placebo. This is direct tissue-level evidence of distribution to muscle in postmenopausal women, not merely a rise in blood metabolites.

Sex Differences in NAD+ Distribution: What We Know and Don't Know

Animal data suggest that male and female rodents have different baseline tissue NAD+ levels and different responses to NAD+ precursor supplementation, with female mice sometimes showing blunted muscle NAD+ responses to NR at the same mg/kg dose used in males. Whether this translates to humans is unknown. The Yoshino 2021 trial provides reassurance that skeletal muscle uptake does occur in postmenopausal women at 250 mg/day NMN, but no head-to-head comparison of NMN tissue distribution by sex in humans exists.

A practical framework for understanding NMN/NR distribution by life stage in women:

| Life Stage | Estrogen Status | Likely NAD+ Biosynthetic Capacity | Human Distribution Data | |---|---|---|---| | Reproductive years | Normal cycling | Higher de novo synthesis via kynurenine pathway | None published | | Perimenopause | Fluctuating, declining | Intermediate, variable | None published | | Postmenopause | Low | Reduced de novo synthesis | Yoshino 2021 (muscle NAD+) | | Pregnancy | High estrogen | Theoretically higher de novo capacity | None; supplement not recommended |

Metabolism: The Enzymatic Steps From Precursor to NAD+

The Salvage Pathway: NMN's Route to NAD+

Inside cells, NMN is converted to NAD+ by the enzyme NMNAT (nicotinamide mononucleotide adenylyltransferase), of which there are three isoforms (NMNAT1, NMNAT2, NMNAT3) localized to the nucleus, cytoplasm/Golgi, and mitochondria respectively. This conversion adds an AMP group to NMN. The reaction is energetically favorable and does not require an intermediate.

NR, by contrast, must first be phosphorylated to NMN by NRK (nicotinamide riboside kinase, isoforms NRK1 and NRK2) before NMNAT can act on it. NRK2 is expressed most highly in muscle and heart. This tissue-specific enzyme expression means NR and NMN may not be equivalent NAD+ precursors in every tissue type, even if they produce similar total-body NAD+ metabolite profiles in blood.

Nicotinamide as a Metabolic Hub and Potential Feedback Inhibitor

When NAD+ is consumed by sirtuins (SIRT1-7) or PARPs during DNA repair, nicotinamide (NAM) is released as a product. NAM is both a substrate for NAD+ resynthesis via NAMPT (the rate-limiting enzyme of the salvage pathway) and a feedback inhibitor of sirtuins at higher concentrations. NAMPT converts NAM back to NMN, completing the salvage cycle. This means the rate of NAD+ regeneration from supplemental NMN ultimately depends on NAMPT activity, which itself declines with age.

Whether NAMPT activity differs by sex or hormonal status in humans is not yet established in controlled human trials. This is a genuine research gap affecting the translation of animal findings to women.

De Novo Synthesis and Estrogen's Influence

The de novo pathway converts dietary tryptophan to NAD+ through the kynurenine pathway, requiring multiple enzymatic steps including the estrogen-responsive enzyme ACMSD. Estrogen downregulates ACMSD, which has the net effect of pushing more tryptophan-derived intermediates toward NAD+ synthesis rather than away from it. This means premenopausal women may have a hormonal advantage in de novo NAD+ production that disappears after menopause. Animal data support this mechanism, but direct human measurement of de novo NAD+ synthesis rates stratified by menopausal status has not been published.

Elimination: How NMN, NR, and Their Metabolites Leave the Body

Urinary Metabolite Profile

NAD+ and its precursors are not excreted intact in meaningful quantities. After cellular use, NAD+ metabolites are methylated in the liver by NNMT (nicotinamide N-methyltransferase) to form N1-methylnicotinamide (MeNAM), which is then further oxidized to N1-methyl-2-pyridone-5-carboxamide (Me-2PY) and N1-methyl-4-pyridone-3-carboxamide (Me-4PY). These methylated metabolites are water-soluble and cleared renally.

Trammell et al. (2016) used isotope-labeled NR to trace urinary metabolite appearance in humans, finding that labeled metabolites (MeNAM, Me-2PY) appeared in urine within 4-6 hours of dosing, confirming renal elimination as the primary excretion route. Half-life of NAD+ itself in human blood is approximately 3-6 hours, though this figure reflects turnover rather than classical pharmacokinetic elimination because NAD+ is continuously consumed and resynthesized.

Implications for Dosing Frequency

The relatively short blood half-life of NAD+ and its precursors is why once-daily dosing is the convention in published trials. Whether twice-daily dosing produces superior tissue-level NAD+ compared with once-daily at the same total dose has not been tested in a human randomized controlled trial.

Renal Considerations

Because methylated metabolites are renally cleared, women with chronic kidney disease or significantly reduced GFR may accumulate MeNAM and related compounds. No dose-adjustment guidance exists because no formal PK studies in renally impaired populations have been conducted for either NMN or NR.

Sex-Specific Pharmacokinetics: What the Data Actually Show

The Evidence Gap

The honest answer is that the pharmacokinetic literature for NMN and NR is almost entirely derived from male participants or mixed-sex cohorts where sex-stratified analyses were not performed or reported. The Irie et al. 2020 single-dose NMN PK study enrolled 12 men. The Trammell et al. 2016 NR study enrolled a mixed cohort but did not report PK parameters by sex.

This is not a minor caveat. Women differ from men in body composition (higher percent body fat, lower lean mass per kg body weight), hepatic enzyme activity including some CYP isoforms, renal clearance rates, and gastrointestinal transit time, all of which could affect NMN and NR absorption, distribution, and elimination. Until sex-stratified PK trials are published, any dose recommendation for women that is extrapolated from male-dominant data carries inherent uncertainty.

What the Yoshino 2021 Trial Adds

The Yoshino 2021 trial is the single most important piece of human evidence specifically in women. In 25 postmenopausal women with prediabetes or overweight randomized to NMN 250 mg/day for 10 weeks, NMN improved skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and increased muscle expression of genes involved in muscle remodeling. The pharmacodynamic signal at 250 mg/day was detectable in postmenopausal women's muscle tissue. This does not establish that 250 mg/day is optimal, only that it produces measurable tissue-level effects in this population.

The trial did not measure plasma NMN PK curves in participants, so it does not resolve the absorption question directly. It does confirm that oral NMN at this dose reaches skeletal muscle in postmenopausal women at pharmacologically relevant concentrations.

Hormonal Cycle Effects on Absorption and Distribution

No published trial has examined NMN or NR pharmacokinetics across the menstrual cycle in premenopausal women. Given that gastrointestinal motility, gastric emptying, and hepatic blood flow vary across the cycle, it is plausible that absorption parameters differ between follicular and luteal phases. This is speculative but physiologically grounded, and it represents a gap that matters for women who are supplementing during their reproductive years.

Pregnancy, Lactation, and Contraception

Plain statement: NMN and NR should not be taken during pregnancy or breastfeeding. This is the conservative and appropriate clinical position given the complete absence of human safety data in these populations.

Pregnancy

No human studies have evaluated NMN or NR pharmacokinetics, safety, or fetal exposure during pregnancy. NMN and NR are dietary supplements, not FDA-approved drugs, and they have not undergone the teratogenicity studies required for prescription medications. NAD+ is essential for embryonic development, and animal studies have shown that NAD+ deficiency causes neural tube defects and limb abnormalities in mouse embryos. Whether supplemental NAD+ precursors at doses used in humans could alter embryonic NAD+ levels in ways that are harmful or beneficial is entirely unstudied in humans.

Given the lack of safety data and the biological plausibility of effects on embryonic development, the only defensible clinical position is to avoid NMN and NR during pregnancy.

Lactation

Whether NMN or NR are excreted in human breast milk is unknown. NR is present in bovine milk naturally at trace levels, suggesting some mammary transfer of NAD+ precursors is physiologically normal. Whether supplemental doses of NMN or NR would substantially increase breast milk concentrations, and whether those concentrations would be safe for an infant, has not been studied. Until data exist, avoidance during breastfeeding is warranted.

Contraception

NMN and NR are not teratogens in the formal pharmacological sense (no confirmed human teratogenicity data exist), but because their fetal safety is unknown, women of reproductive age who are supplementing should use reliable contraception if pregnancy is not desired, and should discontinue supplementation as soon as pregnancy is confirmed or planned. There is no known pharmacokinetic interaction between NMN or NR and hormonal contraceptives.

Who This May Be Right For, and Who Should Avoid It

Postmenopausal Women With Metabolic Concerns

The strongest existing human evidence for NMN specifically in women comes from the postmenopausal, prediabetic population studied by Yoshino et al. If you are postmenopausal, have prediabetes or insulin resistance, and are interested in adjunctive metabolic support alongside lifestyle modification, the evidence base, while early, is more directly applicable to you than to any other female life stage.

Perimenopausal Women

Perimenopause is characterized by erratic estrogen fluctuation, increasing metabolic inefficiency, sleep disruption, and accelerating mitochondrial aging in some tissues. The mechanistic rationale for NAD+ precursor supplementation in perimenopause is reasonable, but no clinical trial has enrolled a specifically perimenopausal cohort. Data would need to be extrapolated from postmenopausal or mixed-age studies, and that extrapolation is imperfect.

Reproductive-Age Women

For women in their reproductive years who are not pregnant and not trying to conceive, the risk-benefit picture is uncertain. NAD+ supports mitochondrial function, DNA repair, and oocyte quality, areas of active research interest. However, no RCT has examined NMN or NR supplementation for fertility outcomes in humans, and the evidence base does not yet support a clinical recommendation for use specifically to improve fertility.

Women With PCOS

PCOS is associated with mitochondrial dysfunction and impaired NAD+ metabolism in some studies. The intersection of PCOS, insulin resistance, and NAD+ biology is mechanistically interesting, but no dedicated NMN or NR trial in women with PCOS has been published as of early 2025. Extrapolation from the insulin-resistance data in Yoshino 2021 is plausible but speculative.

Who Should Avoid NMN and NR

• Pregnant women (no safety data)
• Breastfeeding women (no safety data on milk transfer)
• Women with active malignancy (NAD+ supports cell proliferation, and the theoretical concern about fueling tumor growth exists, though clinical evidence for harm is lacking; discuss with your oncologist)
• Women with significantly impaired kidney function (methylated metabolites are renally cleared; no PK data in this population)

Doses Used in Published Human Trials

Doses across completed human trials range considerably:

• NMN 250 mg/day orally for 10 weeks: Yoshino et al. 2021 (postmenopausal women, insulin sensitivity)
• NMN 250 mg/day orally for 12 weeks: Huang et al. 2023, older adults, muscle strength and physical performance
• NR 250 mg twice daily (500 mg/day) for 6 weeks: Dollerup et al. 2018, obese men
• NR 1000 mg/day for 8 weeks: Martens et al. 2018, middle-aged and older adults

No dose-ranging trial in women has determined a minimum effective dose or a maximum tolerated dose specific to female physiology. The 250 mg/day NMN dose from Yoshino 2021 is the only dose with direct evidence of tissue-level pharmacodynamic effect in postmenopausal women.

Tolerability and Drug Interactions

NMN and NR appear well tolerated in published trials at doses up to 1000 mg/day, with no serious adverse events attributed to either supplement in any completed human RCT. Common reports include mild nausea and flushing (the latter more commonly with NR than NMN at equivalent doses), though rates were not consistently higher than placebo in blinded trials.

Potential pharmacokinetic interactions have not been formally studied. Because NNMT uses S-adenosylmethionine (SAM) as the methyl donor for NAD+ metabolite clearance, high-dose NMN or NR supplementation could theoretically increase SAM consumption. Women taking medications that depend on methylation pathways (methotrexate, certain antiepileptics) should discuss this theoretical interaction with their prescriber. The clinical significance in humans at currently used supplement doses is unknown.